Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.59 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.59 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27260667 | 0.86 | CRBN (0.50) | CRBNDDB1TRPC6 | |
| Hydrochloric Acid SCHEMBL30720184 | 0.85 | CRBN (0.49) | CRBNDDB1TRPC6 | |
| SCHEMBL27260521 | 0.84 | CRBN (0.63) | CRBNDDB1MEN1MAPTTSHR | |
| SCHEMBL27238864 | 0.84 | CRBN (0.63) | CRBNDDB1MEN1MAPTTSHR | |
| SCHEMBL30720114 | 0.84 | CRBN (0.63) | CRBNDDB1MEN1MAPTTSHR | |
| SCHEMBL31382134 | 0.83 | CRBN (0.63) | CRBNDDB1MEN1MAPTTSHR | |
| SCHEMBL30720154 | 0.83 | CRBN (0.58) | CRBNDDB1 | |
| SCHEMBL27260330 | 0.83 | CRBN (0.58) | CRBNDDB1 | |
| SCHEMBL30729282 | 0.81 | CRBN (0.63) | CRBNDDB1 | |
| SCHEMBL21935469 | 0.81 | CRBN (0.59) | CRBNDDB1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028354-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | REGENT OF THE UNIV OF MICHIGAN (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4554948-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Regents of the University of Michigan (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024015409-A1 | CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024015406-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028354-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, ESRRB | CRBN 524/4885DDB1 1861/4885TRPC6 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.